In June 2020, in accordance with the 21st Century Cures Act of 2016 and the Prescription Drug User Fee Act (PDUFA), the U.S. Food and Drug Administration (FDA) launched Project Patient Voice. This patient-focused drug development initiative facilitates systematic approaches to collecting and using meaningful patient and caregiver input, to better inform medical product development and regulatory decision-making, taking the use of real-world evidence (RWE) to a new level.
The Arthritis Foundation, Trio Health (Trio), and American Rheumatology Network (ARN) announce a collaboration to collectively respond to the patient voice as reported in both the Arthritis Foundation’s Live Yes! INSIGHTS study and Trio-ARN’s clinical insights from more than 370,000 rheumatology patients.
American Rheumatology Network (ARN), in partnership with Trio Health, launched ARN Clinical Research to transform drug development for rheumatology research. This technology-driven solution will unite the power of the ARN network with Trio’s proven data management technologies to develop a real-time integrated platform enabling manufacturers to rapidly achieve their goals.
We are pleased to announce we have appointed Michael Cooper as American Rheumatology Network’s (ARN) new CEO, effective immediately. Michael’s appointment reflects ARN’s current state:
To Our Members and Partners, American Rheumatology Network (ARN) and Articularis Healthcare Group Inc., (AHG) stands with the rheumatology community, with the Coalition of State
Each patient is unique. What if their treatment path was too? That possibility is at the core of precision medicine. J. Eugene Huffstutter, MD Precision
Trio Health, a leading technology provider of real-world data and insights on patients announces the launch of the first-ever Patient Voice database in Rheumatology to acknowledge and incorporate the voice of the patient in access programs, clinical development, and brand team care management programs.
Analysis of the American Rheumatology Network-Trio Health (ARN-Trio) registry finds a surge in new prescriptions for Merck’s Renflexis infliximab biosimilar. The ARN-Trio registry is the
We are excited to announce that we are providing all American Rheumatology Network (ARN) physicians with a group membership in the American Medical Association (AMA),
Analysis of the American Rheumatology Network-Trio Health (ARN-Trio) registry finds that AbbVie’s Rinvoq use is increasing rapidly as a proportion of JAK inhibitor use. Rheumatologists
American Rheumatology Network (ARN) and Trio Health (Trio) have launched the first rheumatology registry that combines pharmacy dispensing data with electronic medical records (EMR) to
The American Rheumatology Network (ARN) has been so successful with cost management, particularly via the use of biosimilars, that it believes its model is worthy
by Colin Edgerton We are seeing COVID-19 cases peak in many areas of the US, prompting thoughts about what comes next for rheumatology practices. Many
As of 12:30pm ET on March 17, 2020 CMS has sent out an official notification stating that effective for services starting March 6, 2020 (retroactive),